organization · Reporting owner
Weird Science LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Lunai Bioworks Inc.
Report date February 16, 2018 · Filed February 07, 2023
Section 16 reporting ended · disclosed 2023-02-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,313,499 |
Ending reported balance
After 2022-10-13 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2018-02-16 · Other · Acquired 17,545,283 · Balance 17,545,283 F1: The Reporting Person received these shares as merger consideration in exchange for the Reporting Person's common stock of Enochian BioPharma, Inc., which the Issuer acquired by merger on February 16, 2018. In addition to such shares, the Agreement and Plan of Merger governing the merger (the "Merger Agreement") provides that upon the exercise or conversion of options and warrants to purchase shares of the Issuer's common stock that were outstanding as of the closing of the merger, the Issuer will issue a like number of shares of Common Stock (referred to as "Earn-Out Stock") to the former stockholders of Enochian BioPharma, Inc., including the Reporting Person, on a pro rata basis. The Reporting Person's right to receive additional shares of the Issuer's common stock as Earn-Out Stock became fixed and irrevocable on February 16, 2018, the closing date of the merger. Row 2 · 2018-12-31 · Other · Acquired 1,268,880 · Balance 18,814,163 F2: Shares were received by the Reporting Person as Earnout Stock pursuant to the Merger Agreement. The Reporting Person's right to the Earnout Stock became fixed and irrevocable on February 16, 2018, the date of the closing under the Merger Agreement. Row 3 · 2019-07-30 · Other · Acquired 3,631,234 · Balance 22,445,397 F2: Shares were received by the Reporting Person as Earnout Stock pursuant to the Merger Agreement. The Reporting Person's right to the Earnout Stock became fixed and irrevocable on February 16, 2018, the date of the closing under the Merger Agreement. Row 4 · 2020-05-29 · Other · Disposed 17,545,283 · Balance 4,900,114 F3: Pro rata distribution to the members of the Reporting Person. Row 5 · 2020-12-14 · Other · Acquired 61,249 · Balance 4,961,363 F2: Shares were received by the Reporting Person as Earnout Stock pursuant to the Merger Agreement. The Reporting Person's right to the Earnout Stock became fixed and irrevocable on February 16, 2018, the date of the closing under the Merger Agreement. Row 6 · 2022-04-11 · Other · Acquired 97,032 · Balance 5,058,395 F2: Shares were received by the Reporting Person as Earnout Stock pursuant to the Merger Agreement. The Reporting Person's right to the Earnout Stock became fixed and irrevocable on February 16, 2018, the date of the closing under the Merger Agreement. Row 7 · 2022-04-15 · Other · Disposed 4,961,363 · Balance 97,032 F3: Pro rata distribution to the members of the Reporting Person. Row 8 · 2022-10-13 · Other · Acquired 1,216,467 · Balance 1,313,499 F2: Shares were received by the Reporting Person as Earnout Stock pursuant to the Merger Agreement. The Reporting Person's right to the Earnout Stock became fixed and irrevocable on February 16, 2018, the date of the closing under the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person received these shares as merger consideration in exchange for the Reporting Person's common stock of Enochian BioPharma, Inc., which the Issuer acquired by merger on February 16, 2018. In addition to such shares, the Agreement and Plan of Merger governing the merger (the "Merger Agreement") provides that upon the exercise or conversion of options and warrants to purchase shares of the Issuer's common stock that were outstanding as of the closing of the merger, the Issuer will issue a like number of shares of Common Stock (referred to as "Earn-Out Stock") to the former stockholders of Enochian BioPharma, Inc., including the Reporting Person, on a pro rata basis. The Reporting Person's right to receive additional shares of the Issuer's common stock as Earn-Out Stock became fixed and irrevocable on February 16, 2018, the closing date of the merger.
F2: Shares were received by the Reporting Person as Earnout Stock pursuant to the Merger Agreement. The Reporting Person's right to the Earnout Stock became fixed and irrevocable on February 16, 2018, the date of the closing under the Merger Agreement.
F3: Pro rata distribution to the members of the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 13, 2022 Filed Feb 7, 2023 00:24 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | OtherCommon Stock | 1,216,467 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-23-001671 · marketforms-58228.xml · nonDerivative · entry 8 Weird Science LLC · CIK 0001955760 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,313,499 F2 · kind: Shares were received by the Reporting Person as Earnout Stock pursuant to the Merger Agreement. The Reporting Person's right to the Earnout Stock became fixed and irrevocable on February 16, 2018, the date of the closing under the Merger Agreement. F2 · price: Shares were received by the Reporting Person as Earnout Stock pursuant to the Merger Agreement. The Reporting Person's right to the Earnout Stock became fixed and irrevocable on February 16, 2018, the date of the closing under the Merger Agreement. Read SEC document |
| April 15, 2022 Filed Feb 7, 2023 00:24 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | OtherCommon Stock | 4,961,363 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-23-001671 · marketforms-58228.xml · nonDerivative · entry 7 Weird Science LLC · CIK 0001955760 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,032 F3 · kind: Pro rata distribution to the members of the Reporting Person. F3 · price: Pro rata distribution to the members of the Reporting Person. Read SEC document |
| April 11, 2022 Filed Feb 7, 2023 00:24 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | OtherCommon Stock | 97,032 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-23-001671 · marketforms-58228.xml · nonDerivative · entry 6 Weird Science LLC · CIK 0001955760 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,058,395 F2 · kind: Shares were received by the Reporting Person as Earnout Stock pursuant to the Merger Agreement. The Reporting Person's right to the Earnout Stock became fixed and irrevocable on February 16, 2018, the date of the closing under the Merger Agreement. F2 · price: Shares were received by the Reporting Person as Earnout Stock pursuant to the Merger Agreement. The Reporting Person's right to the Earnout Stock became fixed and irrevocable on February 16, 2018, the date of the closing under the Merger Agreement. Read SEC document |
| December 14, 2020 Filed Feb 7, 2023 00:24 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | OtherCommon Stock | 61,249 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-23-001671 · marketforms-58228.xml · nonDerivative · entry 5 Weird Science LLC · CIK 0001955760 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,961,363 F2 · kind: Shares were received by the Reporting Person as Earnout Stock pursuant to the Merger Agreement. The Reporting Person's right to the Earnout Stock became fixed and irrevocable on February 16, 2018, the date of the closing under the Merger Agreement. F2 · price: Shares were received by the Reporting Person as Earnout Stock pursuant to the Merger Agreement. The Reporting Person's right to the Earnout Stock became fixed and irrevocable on February 16, 2018, the date of the closing under the Merger Agreement. Read SEC document |
| May 29, 2020 Filed Feb 7, 2023 00:24 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | OtherCommon Stock | 17,545,283 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-23-001671 · marketforms-58228.xml · nonDerivative · entry 4 Weird Science LLC · CIK 0001955760 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,900,114 F3 · kind: Pro rata distribution to the members of the Reporting Person. F3 · price: Pro rata distribution to the members of the Reporting Person. Read SEC document |
| July 30, 2019 Filed Feb 7, 2023 00:24 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | OtherCommon Stock | 3,631,234 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-23-001671 · marketforms-58228.xml · nonDerivative · entry 3 Weird Science LLC · CIK 0001955760 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,445,397 F2 · kind: Shares were received by the Reporting Person as Earnout Stock pursuant to the Merger Agreement. The Reporting Person's right to the Earnout Stock became fixed and irrevocable on February 16, 2018, the date of the closing under the Merger Agreement. F2 · price: Shares were received by the Reporting Person as Earnout Stock pursuant to the Merger Agreement. The Reporting Person's right to the Earnout Stock became fixed and irrevocable on February 16, 2018, the date of the closing under the Merger Agreement. Read SEC document |
| December 31, 2018 Filed Feb 7, 2023 00:24 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | OtherCommon Stock | 1,268,880 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-23-001671 · marketforms-58228.xml · nonDerivative · entry 2 Weird Science LLC · CIK 0001955760 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,814,163 F2 · kind: Shares were received by the Reporting Person as Earnout Stock pursuant to the Merger Agreement. The Reporting Person's right to the Earnout Stock became fixed and irrevocable on February 16, 2018, the date of the closing under the Merger Agreement. F2 · price: Shares were received by the Reporting Person as Earnout Stock pursuant to the Merger Agreement. The Reporting Person's right to the Earnout Stock became fixed and irrevocable on February 16, 2018, the date of the closing under the Merger Agreement. Read SEC document |
| February 16, 2018 Filed Feb 7, 2023 00:24 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | OtherCommon Stock | 17,545,283 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-23-001671 · marketforms-58228.xml · nonDerivative · entry 1 Weird Science LLC · CIK 0001955760 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,545,283 F1 · kind: The Reporting Person received these shares as merger consideration in exchange for the Reporting Person's common stock of Enochian BioPharma, Inc., which the Issuer acquired by merger on February 16, 2018. In addition to such shares, the Agreement and Plan of Merger governing the merger (the "Merger Agreement") provides that upon the exercise or conversion of options and warrants to purchase shares of the Issuer's common stock that were outstanding as of the closing of the merger, the Issuer will issue a like number of shares of Common Stock (referred to as "Earn-Out Stock") to the former stockholders of Enochian BioPharma, Inc., including the Reporting Person, on a pro rata basis. The Reporting Person's right to receive additional shares of the Issuer's common stock as Earn-Out Stock became fixed and irrevocable on February 16, 2018, the closing date of the merger. F1 · price: The Reporting Person received these shares as merger consideration in exchange for the Reporting Person's common stock of Enochian BioPharma, Inc., which the Issuer acquired by merger on February 16, 2018. In addition to such shares, the Agreement and Plan of Merger governing the merger (the "Merger Agreement") provides that upon the exercise or conversion of options and warrants to purchase shares of the Issuer's common stock that were outstanding as of the closing of the merger, the Issuer will issue a like number of shares of Common Stock (referred to as "Earn-Out Stock") to the former stockholders of Enochian BioPharma, Inc., including the Reporting Person, on a pro rata basis. The Reporting Person's right to receive additional shares of the Issuer's common stock as Earn-Out Stock became fixed and irrevocable on February 16, 2018, the closing date of the merger. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.